logo

For the Inventor, By the Inventor

Abingdon, United Kingdom

David Festus Charles Moffat

This inventor holds 16 USPTO granted patents and 6 published patent applications and 13 EPO patents. Top assignees: Chroma Therapeutics Limited, Glaxosmithkline Intellectual Property Development Limited, Macrophage Pharma Limited. Active years: 2011-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Festus Charles Moffat. Retrieved from https://idiyas.com/inventor/david-festus-charles-moffat

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 

% Patents Active = 37.5

 

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 100(Granted Patents)


Location History:

  • Oxfordshire, GB (2011 - 2016)
  • Abingdon, GB (2011 - 2019)
  • Windsor Berkshire, GB (2022)

Company Filing History:

goldMedal10 out of 19 
 
Chroma Therapeutics Limited
 patents
silverMedal3 out of 242 
 
Glaxosmithkline Intellectual Property Development Limited
 patents
bronzeMedal3 out of 3 
 
Macrophage Pharma Limited
 patents

Years Active: 2011-2022

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 11382902 - Treatment of cancer by stimulation of IL-12 production (2022-07-12),
2. 10370332 - Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-YL]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof (2019-08-06),
3. 9896417 - Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt,hydrate or solvate thereof (2018-02-20),
4. 9725407 - HDAC inhibitors (2017-08-08),
5. 9636409 - Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters (2017-05-02),
6. 9604940 - 2-aminopyrazine derivatives as CSF-1R kinase inhibitors (2017-03-28),
7. 9388136 - Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof (2016-07-12),
8. 9321718 - Benzamide derivatives and their use as HSP90 inhibtors (2016-04-26),
9. 9273003 - Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate (2016-03-01),
10. 9133104 - Enzyme inhibitors (2015-09-15),
11. 8778953 - Inhibitors of P38 map kinase (2014-07-15),
12. 8217050 - Adenine derivative as inhibitors of HSP90 for the treatment of cancer (2012-07-10),
13. 8148531 - Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity (2012-04-03),
14. 8003695 - IKK-beta serine-threonine protein kinase inhibitors (2011-08-23),
15. 7973181 - Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity (2011-07-05),

Title: The Innovative Mind of David Festus Charles Moffat

Introduction: David Festus Charles Moffat, an accomplished inventor based in Abingdon, GB, has made significant contributions to the field of biochemistry and pharmaceutical research. With a remarkable portfolio that includes 16 patents, Moffat has been at the forefront of developing innovative treatments, particularly in the area of cancer therapy.

Latest Patents: Among his latest patents, Moffat has focused on the "Treatment of cancer by stimulation of IL-12 production." This invention involves compounds such as tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alaninate, which is designed to stimulate IL-12 production and IFN-γ production. The patent also covers the pharmaceutical composition that includes this compound for use in inhibiting the activity of the p38 MAP kinase enzyme, which may have therapeutic benefits for autoimmune and inflammatory diseases as well as cell proliferative diseases. Additionally, the invention describes an acid produced by hydrolysis of the compound's ester group, specifically N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alanine.

Career Highlights: Throughout his career, Moffat has collaborated with reputable organizations to further his innovative endeavors. Notably, he has been associated with Chroma Therapeutics Limited and Macrophage Pharma Limited, where he has contributed to cutting-edge research and development in therapeutics.

Collaborations: Moffat has worked alongside talented individuals such as Stephen John Davies and Alan Hornsby Davidson. These collaborations have played a vital role in the success of his inventions, bringing together expertise and creativity to tackle complex challenges in drug development.

Conclusion: David Festus Charles Moffat exemplifies the spirit of innovation and determination in the scientific community. His groundbreaking patents in cancer treatment illustrate the potential of his work to significantly impact healthcare and provide new hope for patients facing severe illnesses. As he continues to push the boundaries of pharmaceutical research, Moffat's legacy as a visionary inventor is firmly established.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…